Technology
Early Assets
OncoNano is developing a number of early assets that underscore the precision of its micelle technology and core chemistry capability for formulation optimization. ON-BOARD™’s ability to direct payloads preferentially to the tumor microenvironment provides a unique platform for oncology drug development.
Encapsulation within the proprietary polymeric micelle is available for various cytotoxic or protein payloads, including small molecules, antibodies, immune active small proteins and nucleic acids- with the goal to enhance their clinical effects within tumors.
